The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
(This May 16 story has been officially corrected to change the pricing estimate in paragraph 4) (Reuters) - The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen’s tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...